Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MIRM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The filing discloses the departure of the Chief Medical Officer, not the CFO; the red flag trigger appears mislabeled.
Mirum Pharmaceuticals appoints Rob Myers, M.D. as new Chief Medical Officer, succeeding Joanne Quan, M.D.
Filed September 8, 2026 · Period ending September 2, 2026 · ~1 min read
Key Changes
-
high
Board appoints Rob Myers, M.D. as Chief Medical Officer, effective upon his employment start, expected September 21, 2026.
Item 5.02 verify on EDGAR → -
high
Outgoing CMO Joanne Quan, M.D. ceased serving on September 2, 2026; her employment termination is expected October 19, 2026.
Item 5.02 verify on EDGAR → -
medium
Dr. Quan is expected to receive severance benefits under the company's Severance Plan, contingent on an involuntary termination.
Item 5.02 verify on EDGAR → -
medium
Compensation Committee approved extending Dr. Quan's vested stock option exercise period to 12 months post-separation and paying her 2026 target bonus at 100%.
Item 5.02 verify on EDGAR →
Summary
Mirum Pharmaceuticals announced a leadership transition in its medical function. The Board appointed Rob Myers, M.D. as the new Chief Medical Officer, effective when he begins employment, which is expected on September 21, 2026. He succeeds Joanne Quan, M.D., who ceased serving as CMO on September 2, 2026, and whose employment termination is expected on October 19, 2026.
The outgoing CMO is expected to receive severance benefits under the company's Severance Plan, contingent on the separation qualifying as an involuntary termination.
Additionally, the Compensation Committee approved extending the exercise period for her vested stock options to 12 months after separation and paying her 2026 annual target bonus at 100% achievement, subject to customary conditions in a final separation agreement. For investors, the CMO transition is a notable governance event, though the filing does not indicate any disagreement or performance issues. The company has not disclosed the reasons for Dr. Quan's departure, and the appointment of Dr. Myers appears to be a planned succession. The red flag noted in the analysis—departure of CFO—does not match the actual event, which involves the Chief Medical Officer; this discrepancy may warrant clarification.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Mirum Pharmaceuticals appoints Rob Myers, M.D. as new Chief Medical Officer, succeeding Joanne Quan, M.D., who will separate from the company.
Added in current filing · verify on EDGAR →
the Company’s Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company’s Chief Medical Officer, effective upon Dr. Myers’ beginning employment with the Company, which employment is expected to begin on September 21, 2026.
The Board appointed Dr. Myers as the new Chief Medical Officer, effective when he starts employment, expected September 21, 2026. Dr. Quan ceased serving as CMO on September 2, 2026, and her employment termination is expected October 19, 2026.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 9, 2026 · How we verify